GLP-1 Drugs Like Semaglutide Show Promise in Reducing Addiction and Overdose Risk
A landmark study published in Nature Medicine has revealed that semaglutide and other GLP-1 receptor agonists—best known for treating diabetes and obesity—may have unexpected benefits in combating addiction.
Researchers analyzed health records from more than 600,000 U.S. veterans and found that patients taking GLP-1 drugs showed lower rates of developing substance use disorders involving alcohol, nicotine, cannabis, cocaine, opioids, and other substances. Among those already diagnosed with addiction, the medications were associated with fewer overdoses, hospitalizations, emergency room visits, and drug-related deaths.
The mechanism behind this effect is not yet fully understood, though GLP-1 receptors are present in brain regions involved in reward and reinforcement, which are central to addictive behaviors. This suggests the drugs may act directly on neural pathways related to addiction.
Researchers caution that while these observational findings are promising, randomized controlled trials are needed to confirm whether GLP-1 drugs could be deliberately used as a treatment for substance use disorders. The study nonetheless adds to growing evidence that these medications may have broader health applications beyond glucose regulation and weight management.